Buteyko Method for Asthmatic Children With Mouth Breathing
THE EFFECTS OF THE BUTEYKO METHOD IN MOUTH BREATHING ASTHMATIC CHILDREN: A CONTROLLED RANDOMIZED STUDY
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazil, 59078970
- Universidade Federal do Rio Grande do Norte (UFRN)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children from 7 up to 12 years old with asthma diagnose
- Regular inhaled corticosteroids with no change in dose in the preceding 4 weeks.
- Children cannot present: other respiratory disease (such as cystic fibrosis, bronchiectasis, and tuberculosis), retinal detachment, hypertensive crisis, congenital heart defect, pulmonary edema, history of lobectomy or lung segmentectomy, respiratory infections 15 days prior to the evaluations.
Exclusion Criteria:
- Children that are not able to perform some of the necessary procedures, give up participating in the research and present acute symptoms of respiratory tract during the assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Buteyko Method
Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
|
Intervention will be held twice a week during 3 weeks.
|
|
No Intervention: Control
Asthma education.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Sleep disturbance (questionnaire)
Time Frame: Baseline, three weeks later and six months after treatment
|
Sleep disturbance will be assessed by the sleep disturbance scale for children (SDSC).
|
Baseline, three weeks later and six months after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in spirometry (FVC, FEV1, FEV1/FVC, FEF25-75%, PEF)
Time Frame: Baseline, three weeks later and six months after treatment
|
Baseline, three weeks later and six months after treatment
|
|
|
Change in ventilometry (minute volume and vital capacity)
Time Frame: Baseline, three weeks later and six months after treatment
|
Minute volume and vital capacity (liters)
|
Baseline, three weeks later and six months after treatment
|
|
Number of hospitalizations
Time Frame: Through study completion, an average of three weeks and six months after treatment
|
Through study completion, an average of three weeks and six months after treatment
|
|
|
Number of days off-school
Time Frame: During the three weeks of treatment
|
During the three weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1.443.588
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.